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Abstract 
Background 
Present study was conducted to investigate the effects of rosuvastatin combined with fasudil 
on rabbits with dyslipidemia. 
Methods 
Dyslipidemia model of rabbits were produced by prescribing atherogenic diet for 2 weeks. 
Thereafter, 40 rabbits with dyslipidemia were randomly and evenly divided into four groups 
as follow: untreated group (orally prescribed 3 ml of normal saline), rosuvastatin group 
(orally prescribed 3 mg / kg body weight daily, dissolved in 3 ml of normal saline), fasudil 
group (intravenously prescribed 0.5 mg / kg body weight daily, dissolved in 3 ml of normal 
saline), and combined group (the same doses of rosuvastatin and fasudil as aforementioned). 
At baseline, 2 weeks of dyslipidemia establishment and 2 weeks of medical therapy, fasting 
venous blood was drawn for laboratory examination. 
Results 
After 2 weeks’ atherogenic diet treatment, lipid disorders and impaired fasting glucose were 
observed. Systemic inflammation and oxidation were also promoted as revealed by increased 
serum levels of high sensitive C-reactive protein (Hs-CRP) and malondialdehyde (MDA). 
Notably, endothelial function has been impaired significantly as reflected by decreased nitric 
oxide (NO) production and increased serum asymmetric dimethylarginine (ADMA) level. 
RhoA associated kinase (ROCK) activity was also profoundly enhanced (P < 0.05). Inter-
group comparisons showed that when compared to untreated group, modest improvements of 
endothelial function, inflammation and oxidation were observed in rosuvastatin and fasudil 
groups (P > 0.05). These benefits were improved more prominently in combined group (P < 
0.05). Intra-group comparisons also showed that when compared to 2 weeks of dyslipidemia, 
slight improvement of endothelial function, inflammation and oxidation in rosuvastatin and 
fasudil groups were observed (P > 0.05). The improvements were more prominent in the 
combined groups (P < 0.05). 
Conclusion 
Rosuvastatin combined with fasudil conferred synergistic effects on endothelium-protection 
and inflammation- and oxidation-amelioration in the setting of early stage of dyslipidemia. 
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Introduction 
Dyslipidemia, featured by increased serum level of low density lipoprotein cholesterol (LDL-
C), is one of the most important risk factors for atherosclerosis and atherosclerotic 
cardiovascular disease (ASCVD) worldwide [1, 2]. In the early stage of dyslipidemia, 
endothelium becomes dysfunction in accompany with systemic inflammation and oxidation 
[3, 4]. Therefore, effectively treating dyslipidemia at an early stage by lifestyle modification 
or medicines should be beneficial for restoring endothelial function and preventing 
atherosclerosis progression [2]. 
With regard to lipid-lowering medicines, statins is the most commonly used currently. Other 
than lowering cholesterol, statins has other efficacies now universally known as pleiotropic 
effects which are largely dependent upon its potent effects on inhibiting isoprenylation of the 
small GTP-binding proteins during cholesterol biosynthesis [5, 6]. RhoA is the key member 
of small GTP-binding proteins and through activating its main downstream effector, named 
Rho associated kinase (ROCK), RhoA exerts multiple adverse effects on cardiovascular 
system [7, 8]. Fasudil, the specific inhibitor of ROCK, has been found potential to protect 
endothelium and inhibit inflammatory cells infiltration in the basic researches [9, 10]. 
However, no consistent clinical benefits have been achieved in previous studies with the use 
of fasudil on ASCVD therapy. Regarding the potent efficacies of statins and fasudil on 
vascular system, it is reasonable and rational to postulate that statins combined with fasudil 
may render synergistic effects on restoring endothelial function and preventing 
atherosclerosis progression. However, the evidence is lacking. Therefore, we conducted a 
basic research using rabbits with dyslipidemia model and giving different therapeutic 
strategies to address our hypothesis. 
Methods 
Animal preparations 
The protocol for dyslipidemia model production was approved by the Ethic Committee of the 
First Affiliated Hospital of Sun Yat-sen University. Totally 50 male New Zealand White 
rabbits, weighing 1.3–1.5 kg and 5–8 weeks old, were used in present study. After 1 week’s 
accommodation, according to previous research [11], 40 rabbits, used as dyslipidemia model 
production, were randomly selected and treated with 50 g per kilogram body weight per day 
of standard chow diet enriched with 0.5 % cholesterol (Sigma Aldrich, St. Louis, MO, EUA) 
for 2 weeks. The other 10 rabbits, used as the control group, were given standard chow of 50 
g per kilogram body weight per day. All animals received water ad libitum. 
Therapeutic strategies 
After dyslipidemia model was successfully established as revealed by LDL-C elevation, 40 
rabbits with dyslipidemia were randomly and evenly divided into four groups: untreated 
group (orally prescribed 3 ml of normal saline), rosuvastatin group (orally prescribed 3 mg/kg 
body weight daily, dissolved in 3 ml of normal saline), fasudil group (intravenously 
prescribed 0.5 mg/kg body weight daily, dissolved in 3 ml of normal saline), and combined 
group (the same doses of rosuvastatin and fasudil as aforementioned). The therapeutic 
duration was 2 weeks. 
Laboratory examination 
At baseline, 2 weeks of dyslipidemia production and 2 weeks of medical therapy, fasting 
venous blood was drawn for laboratory examination. Lipid profiles including triglyceride 
(TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and LDL-C, 
fasting blood glucose (FBG), liver enzymes including alanine aminotransferase (ALT) and 
aspartase aminotransferase (AST) were detected by Automatic Biochemistry Analyzer 
(Beckman coulter UniCel DxC 800 Synchron). Parameters of endothelial function including 
nitric oxide (NO) production (ELISA kit, Nanjing Jiancheng Bioengineering Institute) and 
serum level of asymmetric dimethylarginine (ADMA, ELISA kit, Shanghai Ying-gong 
Industrial Company) were assessed in accordance to the manufacture’s introduction. Serum 
levels of high sensitive C-reactive protein (Hs-CRP Assay Kit, Immune-turbidimetry method, 
Nanjing Jiancheng Bioengineering Institute) and malondialdehyde (MDA Assay Kit, TBA 
method, Nanjing Jiancheng Bioengineering Institute) were measured to evaluate the changes 
of systemic inflammation and oxidation over time. Serum ROCK activity was detected by 
enzyme-linking immune-absorbent assay (ELISA kit, Yuping BioMedical Company, 
Shanghai, China). 
Statistical analyses 
Data were expressed as means ± S.E.M., and inter-group and intra-group comparisons were 
analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test or by student 
t-test when appropriately using SPSS 19.0 statistical analysis program. P < 0.05 was 
considered as significant. 
Results 
Changes of parameters before and after dyslipidemia establishment 
After 2 weeks of atherogenic diet treatment, inter-group differences were compared. As 
presented in Table 1, after 2 weeks of atherogenic diet treatment, lipid disorders and impaired 
fasting glucose were observed as indicated by increased serum levels of TG, TC, LDL-C and 
FBG. Systemic inflammation and oxidation were also promoted by atherogenic diet treatment 
as revealed by increased serum levels of Hs-CRP and MDA. Notably, with 2 weeks of 
dyslipidemia, endothelial function has significantly impaired as reflected by profoundly 
decreased NO production (Fig. 2) and significantly increased serum level of ADMA. ROCK 
activity was also profoundly enhanced as shown in Fig. 1. Compared to the control group, all 
the between-group differences were statistically significant (P < 0.05). 
Table 1 Inter- and intra-groups comparison of parameters 
Variables Control Untreated Rosuvastatin Fasudil Combined 
At baseline 
     
TG (mmol/L) 1.05 ± 0.11 1.07 ± 0.10 1.06 ± 0.11 1.06 ± 0.12 1.04 ± 0.10 
TC (mmol/L) 3.37 ± 0.25 3.37 ± 0.20 3.34 ± 0.22 3.37 ± 0.21 3.39 ± 0.23 
LDL-C (mmol/L) 1.99 ± 0.14 1.98 ± 0.12 1.99 ± 0.20 2.00 ± 0.19 1.97 ± 0.12 
HDL-C (mmol/L) 1.05 ± 0.04 1.07 ± 0.03 1.05 ± 0.05 1.06 ± 0.04 1.06 ± 0.03 
FBG (mmol/L) 5.83 ± 0.16 5.85 ± 0.15 5.80 ± 0.14 5.80 ± 0.16 5.82 ± 0.12 
ALT (U/L) 33.7 ± 5.4 37.6 ± 3.8 34.1 ± 4.2 37.1 ± 4.9 35.6 ± 3.7 
AST (U/L) 39.1 ± 4.0 37.3 ± 3.2 35.3 ± 3.1 37.5 ± 4.0 36.5 ± 3.0 
Hs-CRP (mg/L) 2.62 ± 0.24 2.59 ± 0.15 2.66 ± 0.22 2.61 ± 0.17 2.63 ± 0.16 
MDA (nmol/L) 0.99 ± 0.16 0.97 ± 0.15 0.93 ± 0.15 0.93 ± 0.15 0.97 ± 0.14 
ADMA (nmol/L) 73.25 ± 10.09 72.32 ± 10.32 70.16 ± 11.08 71.43 ± 11.23 71.89 ± 11.45 
2 weeks of dyslipidemia 
     
TG (mmol/L) 1.06 ± 0.13* 2.14 ± 0.20 2.18 ± 0.21 2.18 ± 0.16 2.16 ± 0.20 
TC (mmol/L) 3.41 ± 0.32* 5.89 ± 0.42 5.87 ± 0.33 5.83 ± 0.32 5.88 ± 0.35 
LDL-C (mmol/L) 1.98 ± 0.14* 3.83 ± 0.42 3.82 ± 0.40 3.84 ± 0.32 3.80 ± 0.26 
HDL-C (mmol/L) 1.05 ± 0.03 1.01 ± 0.02 1.00 ± 0.04 1.01 ± 0.03 1.02 ± 0.02 
FBG (mmol/L) 5.98 ± 0.15* 6.24 ± 0.16 6.29 ± 0.14 6.30 ± 0.15 6.27 ± 0.13 
ALT (U/L) 36.4 ± 5.5 37.1 ± 4.2 36.4 ± 5.0 39.2 ± 4.7 37.7 ± 4.8 
AST (U/L) 38.2 ± 4.7 38.6 ± 3.3 37.9 ± 3.2 37.5 ± 3.3 39.1 ± 3.6 
Hs-CRP (mg/L) 2.73 ± 0.14* 7.28 ± 1.15 7.39 ± 1.06 7.52 ± 1.05 7.40 ± 1.08 
MDA (nmol/L) 0.99 ± 0.12* 4.08 ± 0.40 4.15 ± 0.36 3.99 ± 0.44 4.04 ± 0.37 
ADMA (nmol/L) 74.25 ± 10.33* 87.34 ± 10.08 87.17 ± 11.24 88.62 ± 10.25 86.60 ± 10.45 
2 weeks’ medical therapy 
     
TG (mmol/L) 1.05 ± 0.11* 2.18 ± 0.16 2.09 ± 0.11 2.16 ± 0.13 2.09 ± 0.12 
TC (mmol/L) 3.44 ± 0.30* 5.92 ± 0.36 5.16 ± 0.26** 5.90 ± 0.34 5.18 ± 0.33** 
LDL-C (mmol/L) 1.99 ± 0.17* 3.86 ± 0.35 3.23 ± 0.21** 3.85 ± 0.30 3.20 ± 0.22** 
HDL-C (mmol/L) 1.06 ± 0.04 1.00 ± 0.03 1.03 ± 0.03 1.03 ± 0.04 1.05 ± 0.02 
FBG (mmol/L) 5.92 ± 0.16* 6.21 ± 0.18 6.10 ± 0.17 6.13 ± 0.14 6.10 ± 0.15 
ALT (U/L) 38.2 ± 2.7 37.8 ± 3.2 36.7 ± 2.5 36.9 ± 2.6 35.7 ± 3.3 
AST (U/L) 38.4 ± 3.5 38.9 ± 3.0 37.5 ± 3.6 37.0 ± 3.9 37.9 ± 3.6 
Hs-CRP (mg/L) 2.76 ± 0.11* 7.33 ± 1.12 6.92 ± 1.00 7.00 ± 1.02 6.34 ± 0.96***,**** 
MDA (nmol/L) 0.97 ± 0.15* 4.11 ± 0.36 3.95 ± 0.30 3.91 ± 0.24 3.36 ± 0.35***,**** 
ADMA (nmol/L) 70.46 ± 9.38* 87.88 ± 10.23 83.35 ± 9.68 83.07 ± 10.08 80.14 ± 10.20***,**** 
* P < 0.05 versus other groups, ** P < 0.05 versus Untreated and Fasudil groups, *** P < 0.05 versus Untreated groups, **** P 
< 0.05 versus 2 weeks of dyslipidemia in the same group 
Fig. 1 Inter- and intra-groups comparisons of ROCK activity. Denote: * P < 0.05 versus other 
groups at the same time point; & P < 0.05 versus the Untreated groups at the same time point; 
※ P < 0.05 versus 2 weeks of dyslipidemia in the same group 
Inter-group comparison of parameters after medical therapy 
After 2 weeks of medical therapy, inter-group differences regarding the effects of different 
therapeutic strategies were evaluated and compared. As shown in Table 1, Figs. 1 and 2, lipid 
profiles were improved in the rosuvastatin and combined groups but not in the untreated and 
fasudil groups (P < 0.05). Serum level of FBG was similarly declined in the 3 medical 
therapy groups, however, no significant between-group difference was observed when 
compared to the untreated group. Modest between-group differences were observed in the 
parameters of Hs-CRP, MDA, NO production, ADMA and ROCK activity in the rosuvastatin 
and fasudil groups when compared to the untreated group (P > 0.05). Notably, rosuvastatin 
combined with fasudil therapy had synergistic effects as reflected by the more prominent 
improvement in the parameters of Hs-CRP, MDA, NO production, ADMA and ROCK 
activity when compared to the untreated group (P < 0.05). 
Fig. 2 Inter- and intra-groups comparisons of NO production. Denote: * P < 0.05 versus other 
groups at the same time point; & P < 0.05 versus the Untreated groups at the same time point; 
※ P < 0.05 versus 2 weeks of dyslipidemia in the same group 
Intra-group comparison of parameters after medical therapy 
Intra-group comparisons of parameters were also compared. As shown in Table 1, Figs. 1 and 
2, the parameters of Hs-CRP, MDA, NO production, ADMA and ROCK activity were 
slightly improved in the rosuvastatin and fasudil groups when compared to those at 2 weeks 
of dyslipidemia (P > 0.05). However, the improvement in the parameters of Hs-CRP, MDA, 
NO production, ADMA and ROCK activity were more prominent in the combined groups 
when compared to those of 2 weeks of dyslipidemia (P < 0.05), suggesting that rosuvastatin 
combined with fasudil therapy had synergistic effects on improving endothelial dysfunction, 
inflammation and oxidation induced by dyslipidemia. 
Discussion 
Dyslipidemia is prevalent worldwide and is one of the most important risk factors for 
multiple diseases such as ASCVD. Endothelial dysfunction is implicated in the early stage of 
dyslipidemia as well as in the process of atherosclerosis development [12, 13]. Therefore, 
treating dyslipidemia effectively is of clinical importance. Results from present research 
show that rosuvastatin not only could ameliorate dyslipidemia but also could improve 
endothelial function as well as systemic inflammation and oxidation, which strongly 
supporting the cardio-protective effects of rosuvastatin therapy. Moreover, although no 
effects on lipid-modification, fasudil therapy is effective on improving endothelial function, 
inflammation and oxidation. Expectedly and importantly, fasudil combined with rosuvastatin 
therapy confers synergistic effects on vascular system in the early stage of dyslipidemia 
which should have important clinical relevance. 
Knowingly [14], LDL-C elevation is detrimental to endothelium and could promote systemic 
inflammation and oxidation through multiple mechanisms. Therefore, decreasing LDL-C 
level by statins therapy is of clinical importance in preventing cardiovascular events. Other 
than lipid-lowering effects, statins has other efficacies which are predominantly associated 
with its effects on attenuating small GTP-binding proteins isoprenylation during cholesterol 
biosynthesis. As is well known that RhoA isoprenylation, the most commonly studied small 
GTP-binding protein, could lead to its downstream target ROCK activation thereby eliciting 
multiple adverse effects such as vessel constriction, inflammatory cells migration and 
infiltration, platelet activation, and endothelial dysfunction [15, 16]. Therefore, not only 
decreasing RhoA isoprenylation is critical, inhibiting ROCK activity is also crucial in 
preventing atherosclerosis development and reducing cardiovascular events. For example, 
Naoki Sawada et al. reported that Y-27632, a specific ROCK inhibitor, might be an effective 
therapeutic strategy for treating vascular proliferative disorders and hypertension [17]. In 
addition, results from Anju Nohria showed that inhibition of the Rho/ROCK signaling 
pathway by fasudil should provide a useful strategy to restore NO bioavailability in humans 
with atherosclerosis [18]. Taken together, we postulated that statins combined with ROCK 
antagonist could provide synergistic effects in treating dyslipidemia and its associated 
inflammation and oxidation, and results from our preliminary research supported this 
hypothesis. Of note, in our present research, although fasudil had no benefit on dyslipidemia 
modification, nonetheless, we observed that endothelial function as well as systemic 
inflammation and oxidation were all improved after 2 weeks of fasudil therapy, which 
strongly suggesting that the benefits derived from fasudil therapy was independent of lipid-
lowering. Notably, these benefits were further enhanced by combined therapy which we 
considered was associated with further attenuation of ROCK activity. In light of previous 
reports [6, 19–21], we considered that the two following mechanisms might at least partially 
explain our findings. In the first place, by reducing RhoA isoprenylation during cholesterol 
biosynthesis, rosuvastatin could robustly inhibit ROCK activation thereby enhancing 
endothelial function and ameliorating systemic inflammation and oxidation. On the other 
hand, since fasudil is a specific and potent antagonist for ROCK, therefore, as adjunctive to 
inhibiting ROCK activation by rosuvastatin therapy, fasudil therapy could block the 
downstream effects provoking by already-activated RhoA/ROCK signaling pathway. Taken 
together, through different and complemented mechanisms, rosuvastatin combined with 
fasudil therapy conferred synergistic and protective effects on vascular system in rabbits with 
dyslipidemia. O-linked N-acetylglucosamine (O-GlcNAc) is a reversible post-translational 
modification of serines/threonines substrate and has been found associated with the 
development of dyslipidemia and other cardiovascular diseases [22, 23]. Therefore, detecting 
the change of O-GlcNAc should provide mechanisms regarding the additive benefits of 
combined therapy on rabbits with dyslipidemia. Thus, it is the potential limitation of our 
present research for not investigating the change of O-GlcNAc before and after therapy and 
in the future it is important and warranted to further investigate the relationship between O-
GlcNAc and the application of rosuvastatin and fasudil therapy. 
Interestingly, we observed that dyslipidemia resulted in fasting blood glucose elevation, and 
with rosuvastatin, fasudil or combined therapy, fasting blood glucose was modestly reduced. 
Whether this finding had clinical implications regarding the development of metabolism 
syndrome or diabetes mellitus in the setting of dyslipidemia needed further investigation. 
Moreover, concerning the safety of rosuvastatin and fasudil therapy, liver enzyme was 
serially detected and no significant elevations of ALT and AST were observed, which 
indicated that 2 weeks of rosuvastatin and fasudil therapy was no harm to liver function. 
Conclusion 
Preliminary data from our present research revealed that rosuvastatin combined with fasudil 
therapy conferred synergistic effects on endothelium-protection and inflammation- and 
oxidation-amelioration in the setting of early stage of dyslipidemia. Further study is 
warranted to investigate whether these efficacies could translate into clinical benefits. 
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